TSFAE09:	Subjects With Treatment-emergent Adverse Events by System Organ Class; Safety Analysis Set (Study jjcs - core)							
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
System Organ Class, n (%) 	N=53 	N=73 	N=126 	N=59 	  	  	
General disorders and administration site conditions 	26 (49.1%) 	38 (52.1%) 	64 (50.8%) 	16 (27.1%) 	21.9 (4.3, 39.5) 	24.9 (8.8, 41.1) 	
Skin and subcutaneous tissue disorders 	34 (64.2%) 	28 (38.4%) 	62 (49.2%) 	16 (27.1%) 	37.0 (19.8, 54.2) 	11.2 (-4.7, 27.1) 	
Nervous system disorders 	18 (34.0%) 	18 (24.7%) 	36 (28.6%) 	5 (8.5%) 	25.5 (10.9, 40.1) 	16.2 (4.0, 28.4) 	
Gastrointestinal disorders 	14 (26.4%) 	10 (13.7%) 	24 (19.0%) 	7 (11.9%) 	14.6 (0.1, 29.0) 	1.8 (-9.6, 13.2) 	
Cardiac disorders 	11 (20.8%) 	11 (15.1%) 	22 (17.5%) 	7 (11.9%) 	8.9 (-4.8, 22.6) 	3.2 (-8.4, 14.8) 	
Infections and infestations 	9 (17.0%) 	6 (8.2%) 	15 (11.9%) 	14 (23.7%) 	-6.7 (-21.6, 8.1) 	-15.5 (-28.1, -3.0) 	
Psychiatric disorders 	6 (11.3%) 	8 (11.0%) 	14 (11.1%) 	7 (11.9%) 	-0.5 (-12.4, 11.3) 	-0.9 (-11.8, 10.0) 	
Respiratory, thoracic and mediastinal disorders 	7 (13.2%) 	6 (8.2%) 	13 (10.3%) 	5 (8.5%) 	4.7 (-6.8, 16.3) 	-0.3 (-9.8, 9.2) 	
Investigations 	5 (9.4%) 	7 (9.6%) 	12 (9.5%) 	7 (11.9%) 	-2.4 (-13.8, 9.0) 	-2.3 (-12.9, 8.4) 	
Musculoskeletal and connective tissue disorders 	4 (7.5%) 	5 (6.8%) 	9 (7.1%) 	2 (3.4%) 	4.2 (-4.3, 12.6) 	3.5 (-3.9, 10.9) 	
Injury, poisoning and procedural complications 	3 (5.7%) 	5 (6.8%) 	8 (6.3%) 	2 (3.4%) 	2.3 (-5.5, 10.0) 	3.5 (-3.9, 10.9) 	
Renal and urinary disorders 	2 (3.8%) 	3 (4.1%) 	5 (4.0%) 	2 (3.4%) 	0.4 (-6.5, 7.3) 	0.7 (-5.8, 7.2) 	
Vascular disorders 	1 (1.9%) 	3 (4.1%) 	4 (3.2%) 	3 (5.1%) 	-3.2 (-9.9, 3.5) 	-1.0 (-8.2, 6.2) 	
Ear and labyrinth disorders 	1 (1.9%) 	2 (2.7%) 	3 (2.4%) 	1 (1.7%) 	0.2 (-4.7, 5.1) 	1.0 (-3.9, 6.0) 	
Eye disorders 	1 (1.9%) 	2 (2.7%) 	3 (2.4%) 	2 (3.4%) 	-1.5 (-7.4, 4.4) 	-0.7 (-6.6, 5.3) 	
Reproductive system and breast disorders 	3 (5.7%) 	0 	3 (2.4%) 	3 (5.1%) 	0.6 (-7.8, 8.9) 	-5.1 (-10.7, 0.5) 	
Congenital, familial and genetic disorders 	1 (1.9%) 	1 (1.4%) 	2 (1.6%) 	0 	1.9 (-1.8, 5.5) 	1.4 (-1.3, 4.0) 	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 	1 (1.9%) 	1 (1.4%) 	2 (1.6%) 	0 	1.9 (-1.8, 5.5) 	1.4 (-1.3, 4.0) 	
Endocrine disorders 	0 	1 (1.4%) 	1 (0.8%) 	1 (1.7%) 	-1.7 (-5.0, 1.6) 	-0.3 (-4.6, 3.9) 	
Metabolism and nutrition disorders 	1 (1.9%) 	0 	1 (0.8%) 	2 (3.4%) 	-1.5 (-7.4, 4.4) 	-3.4 (-8.0, 1.2) 	
Surgical and medical procedures 	1 (1.9%) 	0 	1 (0.8%) 	2 (3.4%) 	-1.5 (-7.4, 4.4) 	-3.4 (-8.0, 1.2) 	
Hepatobiliary disorders 	0 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Immune system disorders 	0 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Social circumstances 	0 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	

Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC. 	
Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC.	
Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC.	
Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC.	
Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC.	
Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC.	
Note: Subjects are counted only once for any given SOC, regardless of the number of times they actually experienced an event within the SOC.	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.